Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New findings may help oncologists determine effectiveness of checkpoint inhibitors

In a study published in JCI Insight, researchers have identified checkpoint inhibitor resistance mechanisms in many solid tumour cancers, including melanoma, lung cancer and breast cancer. 

Checkpoint inhibitors (CI) are a type of drug that patients with cancer can take to help block proteins made by certain immune system cells, such as T cells.

In the normal body, the proteins help keep the immune system in check; but also, they keep T cells from attacking cancer cells that a person may have developed.

CI drugs block these proteins, enabling T cells to fight cancer more effectively.

However, with patients’ living longer, tumours are able to evade the therapy and alter their gene expression, ultimately tricking a person’s immune system and checkpoint inhibitors from responding and attacking cancerous cells.

The published research looked at patients who had relapsed after a checkpoint inhibitor course of treatment.

In the study, Davis and his team sought to determine how certain expression patterns on tumour cells could give physicians an idea of whether the patient’s immune system would not respond to checkpoint inhibitors, ultimately causing a lack of response when fighting off cancerous cells.

In fact, a receptor co-discovered by the team several years ago - FCRL6 may serve as a new checkpoint target in these patients, identifying it as a potential immunotherapy option in the future.

“Our findings are significant for anyone who is a candidate for checkpoint inhibitors,” Davis said. “We know that, as patients respond well to treatment and live longer, tumours are smart and will ultimately work to evade one’s immune system. We’re hopeful that we are closer to identifying a new mechanism that could be targeted for future therapies.”

Source: University of Alabama at Birmingham

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation